MedTrace Logo

Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

NCT00842595 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-07-24

No results posted yet for this study

Summary

The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell lymphoma

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

rituximab

6 courses every 28 days

DRUG

vinorelbine

6 courses every 28 days

DRUG

ifosfamide

6 courses every 28 days

DRUG

Mitoxantrone

6 courses every 28 days

DRUG

Prednisone

6 courses every 28 days

Sponsors & Collaborators

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Emmanuel GYAN · French Innovative Leukemia Organisation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2009-11-30
Completion
2010-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842595 on ClinicalTrials.gov